Inspections, Compliance, Enforcement, and Criminal Investigations
|
|
- Camron Valentine McCarthy
- 5 years ago
- Views:
Transcription
1 1 of 5 2/11/ :24 AM Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Baxter Healthcare Corp. 1/17/14 Department of Health and Human Services Public Health Service Food and Drug Administration Chicago District 550 West Jackson Blvd., 15th Floor Chicago, Illinois Telephone: January 17, 2014 WARNING LETTER CHI-2-14 VIA UPS NEXT DAY Robert L. Parkinson, Jr. Chairman, President, and Chief Executive Officer Baxter Healthcare Corporation One Baxter Parkway Deerfield, Illinois Dear Mr. Parkinson: United States Food and Drug Administration (FDA) investigators conducted an inspection of your firm, Baxter Healthcare Corporation (hereafter called Baxter ) located at W. Illinois Route 120 in Round Lake, Illinois from July 9, 2013 through July 29, 2013 and August 29, The investigators determined that Baxter s Round Lake facility is a specification developer for their medical devices, including the Class II medical devices HomeChoice and HomeChoice Pro Automated Peritoneal Dialysis (APD) Systems and IPUMP syringe-style intravenous, epidural or subcutaneous delivery infusion pump. Under Section 201(h) of the Federal Food, Drug and Cosmetic Act (the Act) [21 U.S.C. 321(h)], these products are defined as devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or are intended to affect the structure or function of the body. The inspection revealed that these devices are adulterated within the meaning of Section 501(h) of the Act [21 U.S.C. 351(h)], in that the methods used in, or the facilities or controls used for, their manufacturer, processing, packing, or holding are not in conformity with the current Good Manufacturing Practice (CGMP) requirements of the Quality System (QS) Regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received written responses, dated August 19, 2013, September 27, 2013, October 31, 2013, and November 26, 2013, detailing your firm s corrective actions to the observations noted on the Form FDA-483, Inspectional Observations, issued to Mr. Robert M. Davis on July 29, Your September 27, 2013 response also included Baxter Medical Products Quality System Improvement Plan ( QSIP ). This plan was also discussed with the Agency in a meeting on November 6, We are unable to determine the adequacy or effectiveness of the QSIP at this time because the plan is still being developed. We address the written responses below, in relation to each of the noted violations. The violations include, but are not
2 2 of 5 2/11/ :24 AM limited to, the following: 1. Failure to review, evaluate, and investigate, where necessary, complaints involving the possible failure of a device to meet any of its specifications, as required by 21 CFR (c). Specifically, a. Your firm replaced (b)(4) failed components on the HomeChoice peritoneal dialysis devices, which did not meet your firm s design specification, and you did not investigate the cause of the failure as part of your investigation when the life expectancy of your HomeChoice device is 10 years. b. Your firm s complaint investigations do not include an assessment as to whether there are other similar/same failures on the device to meet specification. For example, your firm had (b)(4) digital printed circuit board failures in the HomeChoice peritoneal dialysis devices since April 2012; however the individual complaint investigations documented that there was no trend. We have reviewed your responses and have determined that they are inadequate because they are incomplete and lack detail. Specifically, CAPA s and , which were initiated to investigate your firm s failure to conduct complaint investigations that were in accordance with procedures and to investigate adequacy of complaint trending, respectively, are either incomplete or lacking of conclusions and corrective actions of the reviews. The adequacy of your firm s responses with respect to trending cannot be determined at this time because trending of as determined problems and cause codes is not complete, and details on this trending were not included as part of the response. The CAPA Event (b)(4) that is included in the written responses provides a plan for the review of procedures and systems for conducting failure investigations trending; however, no detail is provided as to results or conclusions of the assessment. In addition, your response indicated that the HomeChoice does not have a 10-year life expectancy per se, but rather a 10-year service life expectancy. The response references an attachment, HomeChoice Hardware Estimated Design Life (b)(4), which provides a list of estimates for design life for hardware components, including the pump, power supply and battery; however, your response does not address non-hardware components, such as the digital circuit board components and subassemblies. 2. Failure to adequately establish procedures for corrective and preventive actions, as required by 21 CFR (a). Specifically, a. Your firm failed to evaluate whether a corrective or preventive action should be initiated when you received (b)(4) complaints of over infusion in your elastomeric infusion systems. The complaints of over infusions were related to infusions of drugs, including fluorouracil, morphine, vancomycin and fentanyl citrate, which had over delivery times that were between 20 and 48 hours prior to the expected delivery time. Your design specification does not include over infusion as an expected result b. Your firm failed to follow procedure (b)(4), Corrective Action Preventive Action (CAPA) Procedure in that you failed to open a CAPA when changes were made to your supplier control procedures as part of a continuous improvement project. The procedural changes were made to supplier control procedures, including (b)(4), to address the handling of suppliers that do not agree to be audited by your firm and/or sign Baxter s quality agreement. The changes affected approximately (b)(4) suppliers. The adequacy of your firm s response for part (a) cannot be determined at this time because the corrective actions, such as (b)(4), CAPA Event (b)(4) and a plan to remediate Design History Files, are all in progress, and we cannot determine their effectiveness at this time. The adequacy of your firm s response to part (b) cannot be determined at this time because the corrective actions, such as the CAPA Event (b)(4) which was initiated to document the process improvements and to track the plan s effectiveness and CAPA Event (b)(4) which was initiated to investigate the lack of adherence to the CAPA procedure, are not yet complete.
3 3 of 5 2/11/ :24 AM 3. Failure to establish and maintain corrective and preventive action procedures that include requirements for ensuring the corrective and preventive action is effective, as required by 21 CFR (a)(4). Specifically, your firm failed to identify and document the verification of the effectiveness of the action taken for (b)(4) closed CAPAs. The adequacy of your firm s responses cannot be determined at this time because the corrective actions, such as CAPA Event (b)(4), which was generated in order to perform a detailed review and root cause investigation of the (b)(4) closed events, are incomplete. In addition, your firm was cited for this same issue during the previous inspection and your June 27, 2012 response indicated that your firm would document and provide rationale when no effectiveness check is performed; however, this inspection showed that your firm did not adequately implement this previous corrective action. 4. Failure to adequately establish procedures for identifying valid statistical techniques required for establishing, controlling, and verifying the acceptability of process capability and product characteristics have not been adequately established, as required 21 CFR (a). Fo example, your statistical tool for CAPA data trending is inadequate for the intended use for identifying problems to assess whether a preventive action or corrective action is indicated. Your firm received 186,822 complaints between April 17, 2012 and July 2013, and your current process is to check your trending tool for a known trigger when you receive a complaint. This is inadequate in that: a. The statistical trigger tool is published once a month, and if the complaint personnel are looking at the trending tool at the end of the month, you are not assessing approximately (b)(4) complaints to determine if there are same/similar problems to investigate collectively. b. The statistical trending tool, which is used to identify complaint triggers, is not based on whether the device meets its intended use and user needs. c. Review of more than (b)(4) CAPA investigations that were initiated due to triggers from the complaint trending tool, such as CAPA Event PR (b)(4), revealed that all of the CAPA investigations were closed with no action taken by your firm. We have reviewed your responses and have determined that they are inadequate because it is unclear from the responses how the CAPA that was initiated to address this observation, CAPA (b)(4), will address FDA s concerns regarding the frequency of the trending, and the failure to identify complaint triggers based on risk and whether the device meets its intended use and user needs. 5. Failure to adequately establish procedures for design validation, as required by 21 CFR (g). Specifically, a. Your current design controls for the coil tube infusor are inadequate in that the mitigation for your design risk analysis for over infusion does not identify the mitigation actions implemented to address/prevent over infusion in your intravenous drug/fluid delivery systems. Your risk analysis documents the design inputs as your mitigation factors when design inputs are defined as the physical and performance requirements of a device that are used as a basis for device design. There were (b)(4) incidences of over infusion in your (b)(4) devices, including the coil tube infusor, since the previous inspection. b. Your current design control risk analysis for the coil tube infusor is inadequate in that your mitigation for over infusion does not identify the mitigation actions implemented to address/prevent over infusions. Your risk analysis mitigation states that the device will be manufactured on validated processes and will have manufacturing testing. These steps are considered part of design transfer; they do not identify mitigations to address/prevent over infusions in your intravenous drug/fluid delivery system. We have reviewed your responses and have determined that although your firm has committed to discontinuing distribution and sale of the coiled tube infusor products in the U.S. market no later than December 31, 2013, your responses lack detail on how your firm is addressing the failure to properly
4 4 of 5 2/11/ :24 AM identify risk analysis mitigation across all product lines. 6. Failure to adequately establish procedures to ensure equipment is routinely calibrated, inspected, checked, and maintained, as required by 21 CFR (a). Specifically, a. Your firm performed renal and fluid system intravenous administration set design verification testing using 25 non-validated test methods which you created in house. The use of non-validated test methods does not ensure that design test method results were valid. b. Your firm failed to follow your procedures to ensure that instruments used in intravenous administration set and peritoneal dialysis administration set design verification packaging and complaint investigation packaging are calibrated. Review during the inspection found (b)(4) instruments that were not calibrated. The adequacy of your responses cannot be determined at this time because many of the corrective actions that were initiated in the responses to the observation, including CAPA Events (b)(4) and (b)(4), are either not yet complete or evidence of their effective implementation has not been verified. You should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the Food and Drug Administration withou further notice. These actions include, but are not limited to, seizure, injunction, and/or civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Please notify this office in writing within fifteen (15) working days from the date you receive this letter of the specific steps you have taken to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. Include documentation of the corrective action you have taken. If your planned corrections will occur over time, please include a timetable for implementation of those corrections. If corrective action cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed. Your response should be sent to: Carrie Ann Plucinski, Compliance Officer, Food and Drug Administration, 550 W. Jackson Blvd., 15 th floor, Chicago, IL Refer to the Unique Identification Number (CMS Case # ) when replying. If you have any questions about the content of this letter, please contact Ms. Plucinski at Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your facility. It is your responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, Form FDA-483 (FDA-483), issued at the close-out of the inspection may be symptomatic of serious problems in your firm s manufacturing and quality assurance systems. FDA expects your corporate management to undertake a comprehensive and global assessment of your operations immediately to ensure that medical devices conform to FDA requirements. Sincerely, /S/ Scott J. MacIntire District Director cc: Mark W. Jackson Vice President Global Quality Baxter Healthcare Corporation W. Illinois Route 120 Round Lake, Illinois Page Last Updated: 02/10/2014
5 5 of 5 2/11/ :24 AM Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players. Accessibility Contact FDA Careers FDA Basics FOIA No Fear Act Site Map Transparency Website Policies U.S. Food and Drug Administration New Hampshire Avenue Silver Spring, MD Ph INFO-FDA ( ) FDA For Government For Press Combination Products Advisory Committees Science & Research Regulatory Information Safety Emergency Preparedness International Programs News & Events Training and Continuing Education Inspections/Compliance State & Local Officials Consumers Industry Health Professionals FDA Archive Links on this page:
BE-595M Homework Assignment Due: 3/3/08
BE-595M Homework Assignment Due: 3/3/08 Attached is a Warning Letter issued to Applied Water Engineering, Inc., Salt Lake City, UT, for violations of the Quality System Regulations. The firm manufactures
More informationBristol Myers Squibb Holdings Pharma., Ltd.
Bristol Myers Squibb Holdings Pharma., Ltd. Department of Health and Human Services Public Health Service Food and Drug Administration 466 Fernandez Juncos Avenue Puerta De Tierra San Juan, Puerto Rico
More informationAMENDED WARNING LETTER CIN
Department of Health and Human Services Public Health Service Food and Drug Administration Cincinnati District Office Central Region 6751 Steger Drive Cincinnati, OH 45237-3097 Telephone: (513) 679-2700
More informationWARNING LETTER CERTIFIED MAIL -~ Q December 14, 2005
-~ Q DEPARTMENT Or HEALTI-I A\D HUMAN SERVICES Public Health Service Food and Drug Administration Central Region Telephone (973) 526-6006 New Jersey District Waterview Corporate Center 10 Waterview Blvd.,
More information:,-, WARNING LETTER. Mr. Jean Claude Mas Chief Executive Officer Poly Implants Protheses, Sa 337 Avenue De Bruxelles La Seyne, Sur Mer France
+., %- *: $1.,X,, *,+,,r + $, DEPARTMENT +, %, >,,, :,-, OF HEALTH & HUMAN SERVICES Public Health Service VIA FEDERAL EXPRESS ~ 22moo WARNING LETTER Mr. Jean Claude Mas Chief Executive Officer Poly Implants
More information950 t2.d Public Heallh Service
DEPARTMENT OF HEALTH & HUMAN SERVICES CERTIFIED MAIL RETURN RECEIPT REQUESTED 950 t2.d Public Heallh Service Food and Drug Administration Detroit District 300 River Place Suite 5900 Detroit, MI 48207 Telephone:
More informationGuidance for Industry
Guidance for Industry Self-Identification of Generic Drug Facilities, Sites, and Organizations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
More informationCase: 1:10-cv Document #: 74-1 Filed: 04/15/11 Page 1 of 7 PageID #:2403 EXHIBIT A
Case: 1:10-cv-06016 Document #: 74-1 Filed: 04/15/11 Page 1 of 7 PageID #:2403 EXHIBIT A Case: 1:10-cv-06016 Document #: 74-1 Filed: 04/15/11 Page 2 of 7 PageID #:2404 UNITED STATES DISTRICT COURT NORTHERN
More information2015 Annual FDA Medical Device Quality System Data. Inspections, FDA Form 483 Observations, and Warning Letter Citations
2015 Annual FDA Medical Device Quality System Data Inspections, FDA Form 483 Observations, and Warning Letter Citations Why is FDA making these data available? In support of the FDA s Transparency and
More informationWARNING LETTER VIA FEDERAL EXPRES S
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville, Maryland 20850 WARNING LETTER VIA FEDERAL EPRES S George W. LeMaitre Chairman
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Inspections, Compliance, Enforcement, and Criminal Investigations Husain, Mustafa M, M.D. 23-Jul-08 Department of Health and Human Services Public Health Service Food and Drug Administration Center for
More informationFDA's OMB supporting document for QSr recordkeeping, 7/20/01, page 1 of 7
FDA's OMB supporting document for QSr recordkeeping, 7/20/01, page 1 of 7 DISCLAIMER: This document was prepared by editing the converted PDF file supporting FDA's request to OMB for continuation of record
More informationSJN DO CB Field Alert Reports. Edwin Ramos Director of Compliance Food and Drug Administration San Juan District Office
SJN DO CB Field Alert Reports Edwin Ramos Director of Compliance Food and Drug Administration San Juan District Office SJN DO Mission Assuring that safe and effective drugs are available to the public
More informationMedical Devices: Do I Need to Open a CAPA?
Medical Devices: Do I Need to Open a CAPA? Adrienne Franco Busby, Partner, Faegre Baker Daniels LLP Anne Miller, Principal Regulatory Counsel, Medtronic Marta L. Villarraga, Principal, Exponent, Inc. Moderated
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 3%3&4
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 3%3&4 JUL 1 3 2CG3 WARNING LETTER Food and Drug Administration Center for Devices and Radiological Health 2098 Gaither Road Rockville, MD 20850
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Inspections, Compliance, Enforcement, and Criminal Investigations Dallas Jr, Anthony V, MD 11/09/09 Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring,
More informationWARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 WARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED Charles J. Coté, M.D. Ref: 09-HFD-45-02-04
More informationCenter for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1
Center for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1 Donald D. Ashley, JD 2017 FDLI Enforcement, Litigation, and Compliance Conference: For the Drug,
More informationConnie Hoy October 2013
Connie Hoy October 2013 Warning letter issued to firm for complaint handling Failure to report within 30 days Failure to implement adequate procedures Failure to establish standard review process No procedure
More information+.,m 7. yw ~ ~ & DEC FEDERAL EXPRESS
+,*,s WC, ~ *4+ S* DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service, % %,+ 747 +,m 7 Food and Drug Administration 5 Jg FEDERAL EXPRESS 2088 Gaither Road Rockville MD 20850 yw ~ ~ & 4 DEC 21997
More informationFSMA Enforcement: The First Year
FSMA Enforcement: The First Year Scott J. MacIntire Director, Division of Enforcement FDA Office of Regulatory Affairs December 6, 2017 Topics to Include Compliance & Enforcement FSMA Inspections Human
More informationPREVENT YOUR DIETARY SUPPLEMENT LABORATORY FROM BECOMING A COMPLIANCE RISK. Marian Boardley 2013
PREVENT YOUR DIETARY SUPPLEMENT LABORATORY FROM BECOMING A COMPLIANCE RISK Marian Boardley 2013 APPLICABLE GMP S: DIETARY SUPPLEMENT LABS Subparts for laboratory operations and testing, 21 CFR 111 D Equipment
More information. s%rwcu ~,+ *+ % %vd3a 7 Food and Drug Administration. Center for Devices and
* %. s%rwcu ~,+ *+ Jf ~ DEPARTMENT OF HEAITH & HUMAN SERVICIB Public Health Setvice z 2 4/5924 % % %vd3a 7 Food and Drug Administration. Center for Devices and Radiological 2098 Gaither Road Via Federal
More informationClinical Research Seminar
Clinical Research Seminar HOW TO DEVELOP A CORRECTIVE AND PREVENTIVE ACTION PLAN (THAT EVEN THE IRB AND FDA WILL LOVE) April 11, 2018 Fiona Rice, MPH Human Research Quality Manager fionar@bu.edu Mary-Tara
More informationInvestigator Roles and Responsibilities in Clinical Device Trials
Investigator Roles and Responsibilities in Clinical Device Trials A Total Product Lifecycle Approach to Medical Device Development: Responsibilities and Opportunities The Stanford Center for Clinical and
More informationThe U.S. Food and Drug Administration s Food Safety Modernization Act: Current & Future Requirements
The U.S. Food and Drug Administration s Food Safety Modernization Act: Current & Future Requirements Beatrice Moreau Senior Regulatory Advisor Registrar Corp 144 Research Drive Hampton, Virginia USA 23666
More informationRecall: Physio-Control Inc., issued an URGENT Medical Device Recall: Due to Artwork Depicts Incorrect Electrode Placement for Infants
USAF Dental Evaluation & Consultation Service Recall: Physio-Control Inc., issued an URGENT Medical Device Recall: Due to Artwork Depicts Incorrect Electrode Placement for Infants This recall is being
More informationStaff Responsible Procedure Rationale/Reason
Subject: Patient Controlled Analgesia Date: October 2011 UPMC St. Margaret UPMC St. Margaret Harmar Outpatient Center Clinical Practice Council Policy #2005 Overview: To promote appropriate PCA use and
More informationOutage dates (duration): September 5, 1996 to May 27, 1999 (2.7 years) Reactor age when outage began: 8.8 years
Clinton Illinois, IL Owner: Illinois Power Company Reactor type: Boiling water reactor Commercial operations began: November 24, 1987 Outage dates (duration): September 5, 1996 to May 27, 1999 (2.7 years)
More informationFinancial Conflict of Interest: Investigator Procedures. Office of Research, Innovation, and Economic Development Research Integrity and Compliance
Financial Conflict of Interest: Investigator Procedures Office of Research, Innovation, and Economic Development Research Integrity and Compliance June 2018 2 Table of Contents Introduction... 3 Private,
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES WARNING LETTER. (b) (4) clinical investigation (Protocol entitled A Phase II, Multicenter,
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 WARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED Ronald Bukowski, M.D. 28099 Gates Mills
More informationSeptember 1, Comments on Draft Reportable Food Registry (RFR) Guidance; Docket No. FDA-2009-D-0260
Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, Maryland 20852 Re: Comments on Draft Reportable Food Registry (RFR) Guidance; Docket No. FDA-2009-D-0260
More informationTo describe the process for the management of an infusion pump involved in an adverse event or close call.
TITLE INFUSION PUMPS FOR MEDICATION & PARENTERAL FLUID ADMINISTRATION SCOPE Provincial, Clinical DOCUMENT # PS-70-01 APPROVAL LEVEL Executive Leadership Team SPONSOR Provincial Medication Management Committee
More informationc+!!!! # -) NW DEPARTMENT OF HEALTH& HUMAN SERVICES Food and Drug Administration CBER Certified Mail Return Receipt Requested
c+!!!! # -) i v L DEPARTMENT OF HEALTH& HUMAN SERVICES Food and Drug Administration CBER-01-006 WI% Center for Biologics Evaluation and Research 1401 Rockville Pike Rockville MD 20852-1448 NW 302000 WARNING
More information10/4/12. Controlled Substances Dispensing Issues and Solutions. Objectives. Financial Disclosure
Controlled Substances Dispensing Issues and Solutions Ronald W. Buzzeo, R.Ph. Chief Compliance Officer November 7, 2012 CE Code: Financial Disclosure I have no actual or potentially relevant financial
More informationWorking with your Liquor Control Agent Illinois Higher Education Center Webinar January 26, 2012
Working with your Liquor Control Agent Illinois Higher Education Center Webinar January 26, 2012 Training Objectives Understand the role of the Illinois Liquor Control Commission (ILCC) and Local Liquor
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
60-4 (v4 ( ~' DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service. Food and Drug Administration 9200 Corporate Boulevard el Rockville, Maryland 20850 MAY - 6 2008 VIA FEDERAL EXPRES S Merrill W.
More informationWARNING LETTER. an both of which were sponsored by. (formerly ). The products
g5~5s c Public Health Service ' SLRV7CLS r r f+ ~1Mr~la DEPARTMENT OF HEALTH & HUMAN SERVICES DEC 2 1 2005 Food and Drug Administration 9200 Corporate Blvd. Rockville, Maryland 20850 WARNING LETTER Via
More informationContains Nonbinding Recommendations
Establishing and Maintaining a List of U.S. Milk and Milk Product, Seafood, Infant Formula, and Formula for Young Children Manufacturers/Processors with Interest in Exporting to China: Guidance for Industry
More informationNEW JERSEY ESRD REGULATORY UPDATE
NEW JERSEY ESRD REGULATORY UPDATE New Jersey Department of Health Stefanie Mozgai, BA, RN, CPM, Director Anna Sousa, MS, RD, Supervising Healthcare Evaluator October 2014 REPORTABLE EVENTS New Jersey Department
More informationRegulatory,Quality & Emergency Preparedness. MaryBeth Parache Director, Quality Affairs New York Blood Center
Regulatory,Quality & Emergency Preparedness MaryBeth Parache Director, Quality Affairs New York Blood Center 1 Regulatory 2 Who regulates us? Food and Drug Administration (FDA) Blood, tissue, HCT/P, medical
More informationSession 3 FDA Audits and Findings
Session 3 FDA Audits and Findings Byungja Marciante, Investigator US Food and Drug Administration Shanghai Centre-Suite 723 1376 Nanjing Xi Lu Shanghai, PRC 200040 美国食品药品管理局上海商城 723 室南京西路 1376 号中国上海 200040
More informationChanges to QSR. The table below provides a history of changes to FDA s Quality System Regulation (QSR)
Changes to QSR The table below provides a history of changes to FDA s Quality System Regulation (QSR) The citation is to the Federal R: the first number is the volume, FR indicates the Federal Register,
More informationI. Preamble: II. Parties:
I. Preamble: MEMORANDUM OF UNDERSTANDING BETWEEN THE FEDERAL COMMUNICATIONS COMMISSION AND THE FOOD AND DRUG ADMINISTRATION CENTER FOR DEVICES AND RADIOLOGICAL HEALTH The Food and Drug Administration (FDA)
More informationThe AICPA Peer Review Board appreciates your cooperation and efforts in making the peer review program a success.
May 4, 2018 Todd M. Shapiro, President & CEO Russell Wilson, Peer Review Committee Chair Illinois CPA Society 550 W Jackson, Ste. 900 Chicago, IL 60661-5742 Dear Mr. Shapiro & Mr. Wilson: On April 11,
More informationProtecting, Maintaining and Improving the Health of Minnesotans
CMS Certification Number (CCN): 245210 Delivered electronically September 25, 2014 Mr. Rob Lahammer, Administrator Lake Minnetonka Shores 4527 Shoreline Drive Spring Park, Minnesota 55384 Protecting, Maintaining
More informationEffective Date: 11/09 Policy Chronicle:
Title: Investigational Drug Service Functions Policy Type: Clinical Operations Replaces (supersedes): Title: N/A Policy Chronicle: Date Original Version of Policy was Effective: 09/06 Reviewer Signature:
More informationPHMSA Damage Prevention & Excavation Enforcement
PHMSA Damage Prevention & Excavation Enforcement Pipeline Safety Trust Conference November 2017 Dave Mulligan Community Liaison PHMSA Damage Prevention Program Rulemaking and Policies Promote prevention
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE MEDICATION ORDERS SCOPE Provincial APPROVAL AUTHORITY Clinical Operations Executive Committee SPONSOR Provincial Medication Management Committee PARENT DOCUMENT TITLE, TYPE AND NUMBER Medication
More informationMedical Devices and Device-Led Combination Products; Voluntary Malfunction Summary
This document is scheduled to be published in the Federal Register on 08/17/2018 and available online at https://federalregister.gov/d/2018-17770, and on govinfo.gov 4164-01-P DEPARTMENT OF HEALTH AND
More informationNC General Statutes - Chapter 90A Article 2 1
Article 2. Certification of Water Treatment Facility Operators. 90A-20. Purpose. It is the purpose of this Article to protect the public health and to conserve and protect the water resources of the State;
More informationCompounded Sterile Preparations Pharmacy Content Outline May 2018
Compounded Sterile Preparations Pharmacy Content Outline May 2018 The following domains, tasks, and knowledge statements were identified and validated through a role delineation study. The proportion of
More informationPostmarketing Drug Safety and Inspection Readiness
Postmarketing Drug Safety and Inspection Readiness June 19, 2018 Center for Drug Evaluation and Research (CDER) Small Business and Industry Assistance (SBIA) Webinar United States Food and Drug Administration
More informationWARNING LETTER. Dear Dr. Wright : DEPARTMENT OF HEALTH & HUMAN SERVICES CERTIFIED MAIL RETURN RECEIPT REQUESTED
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 WARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED Richard A. Wright. M.D. Ref: 09-HFD-45-02-0
More information4 ( DEPARTMENT OF HEALTH& HUMAN SERVICES Public Health Service
4 ( DEPARTMENT OF HEALTH& HUMAN SERVICES Public Health Service X+m CBER40-018 0 ] =-?-7/7 Food and Drug Administration Center for Biologics Evacuation and Research 1401 Rockville Pike Rockville MD 20852-1448
More information2018 ABOS Part II Oral Examination
2018 ABOS Part II Oral Examination Information Packet: Preparing Your Case List Page 1 of 20 2018 American Board of Orthopaedic Surgery (ABOS) Part II Oral Examination Dear ABOS Part II Oral Candidate:
More information... f%odand DrugAdministration via Federal Express 2098 Gaither Road
~ S-C(,* #+ % f $ s 5 G += > DIZPARTMENT OF JjIEALTH & HUMAN SJZRVICES Public Health Sewice c I 176 T+) f%odand DrugAdministration via Federal Express 2098 Gaither Road RockviUe MD 20850 WARNING LETTER
More informationStandards for Community-Based Care Registered Nurse Delegation
Division 47 Standards for Community-Based Care Registered Nurse Delegation 851-047-0000 Rule Summary, Statement of Purpose and Intent These rules provide standards and guidance for nurses to delegate specific
More informationWIRBinar. How to Survive an FDA Inspection. Upcoming Trainings: Contact Us: (360)
WIRBinar How to Survive an FDA Inspection 10-26-2011 Brought to you by WIRB Education and Consulting Services. Improve your ability to maintain compliance and protect human subjects with guidance from
More informationH 7608 S T A T E O F R H O D E I S L A N D
LC00 01 -- H 0 S T A T E O F R H O D E I S L A N D IN GENERAL ASSEMBLY JANUARY SESSION, A.D. 01 A N A C T RELATING TO HEALTH AND SAFETY -- THE CONSUMER PROTECTION IN EYE CARE ACT Introduced By: Representatives
More informationMay 12, 2016 MEMORANDUM. Certain provisions of FSMA are already in effect, namely: Mandatory recall authority (FSMA 206).
L A W O F F I C E S 7 0 0 T H I R T E E N T H S T R E E T, N. W. S U I T E 1 2 0 0 W A S H I N G T O N, D. C. 2 0 0 0 5-5 9 2 9 ( 2 0 2 ) 7 3 7-5 6 0 0 F A C S I M I L E ( 2 0 2 ) 7 3 7-9 3 2 9 w w w.
More information: study utilizing trieib)(4) b)(4) I I""-", _
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville, Maryland 20850 WARNING LETTER VIA FEDERAL EXPRESS Sarah H. Lisanby, M.D. 1051
More informationAUDIT REPORT. Audit of Official Controls carried out by the Health Service Executive (Regulation (EC) No 853/2004)
AUDIT REPORT Audit of Official Controls carried out by the Health Service Executive (Regulation (EC) No 853/2004) AUDIT REPORT Audit of Official Controls carried out by the Health Service Executive (Regulation
More informationtwj arid Cltug AJmiist : a tuxt --.,~ 9200 (:wpcuat : IlkJ Ko:.l, v ille A4Il
5~ := DEPARTMENT OF HEALTH & HUMAN SERVICE S.'' P116 :1, I Ir31th Serrsc e twj arid Cltug AJmiist : a tuxt --.,~ 9200 (:wpcuat : IlkJ Ko:.l, v ille A4Il 2085 0 2 6 L ~l! WARNING LETTER Via Federal Express
More informationU. S. Coast Guard Sector
U. S. Coast Guard Sector Auxiliary Assistant Suspension and Revocation Investigator Performance Qualification Standard [This page left intentionally blank] Sector Training Guide Auxiliary Assistant Suspension
More informationSTATE OF NORTH CAROLINA OFFICE OF STATE PERSONNEL 1331 Mail Service Center Raleigh, North Carolina August 16, 2012
STATE OF NORTH CAROLINA OFFICE OF STATE PERSONNEL 1331 Mail Service Center Raleigh, North Carolina 27699-1331 BEVERLY EAVES PERDUE GOVERNOR ANN G. COBB, DEPUTY DIRECTOR INTERIM STATE PERSONNEL DIRECTOR
More information107 FERC 61,053 UNITED STATES OF AMERICA FEDERAL ENERGY REGULATORY COMMISSION
107 FERC 61,053 UNITED STATES OF AMERICA FEDERAL ENERGY REGULATORY COMMISSION Before Commissioners: Pat Wood, III, Chairman; Nora Mead Brownell, Joseph T. Kelliher, and Suedeen G. Kelly. Reporting By Transmission
More informationResearch Audits PGR. Effective: 12/04/2013 Reviewed: 12/04/2015. Name of Associated Policy: Palmetto Health Administrative Research Review
Effective: 12/04/2013 Reviewed: 12/04/2015 Name of Associated Policy: Palmetto Health Administrative Research Review Definitions Responsible Positions Equipment Needed Procedure Steps, Guidelines, Rules,
More informationQuality Management of Apheresis Personnel
In: McLeod BC, Price TH, Weinstein R, eds. Apheresis: Principles and Practice, 2nd Edition Bethesda, MD: AABB Press, 2003 Quality Management of Apheresis Personnel 32 Quality Management of Apheresis Personnel
More informationUpdate on FSMA Implementation. Rebecca Buckner May 24, 2016
Update on FSMA Implementation Rebecca Buckner May 24, 2016 Presentation Overview FSMA Implementation Rulemaking and Industry Guidance - Focus on the Preventive Controls Rules FSMA Implementation Guiding
More informationTESTIMONY OF THOMAS HAMILTON DIRECTOR SURVEY & CERTIFICATION GROUP CENTER FOR MEDICAID AND STATE OPERATIONS CENTERS FOR MEDICARE & MEDICAID SERVICES
TESTIMONY OF THOMAS HAMILTON DIRECTOR SURVEY & CERTIFICATION GROUP CENTER FOR MEDICAID AND STATE OPERATIONS CENTERS FOR MEDICARE & MEDICAID SERVICES ON CLIA AND GENETIC TESTING BEFORE THE SENATE SPECIAL
More informationExecutive Summary 56,173 Purpose and Coverage of the Rule 56,173 Summary of the Major Provisions of the Rule 56,173 Costs and Benefits 56,175
Executive Summary 56,173 Purpose and Coverage of the Rule 56,173 Summary of the Major Provisions of the Rule 56,173 Costs and Benefits 56,175 I. Background 56,176 A. FDA Food Safety Modernization Act 56,176
More informationVersion 1.1, 6/30/2016 Guidance for Abbreviated IDE Requirements
Version 1.1, 6/30/2016 Guidance for Abbreviated IDE Requirements The Principal Investigator of a study that is requesting an abbreviated IDE for use of a non-significant risk device must attest to the
More informationOffice of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators
Office of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators Patricia Fischer, RN, CCRP Investigator Responsibilities FDA Draft Guidance May 2007 Clarifies FDA s expectations,
More information(9) Efforts to enact protections for kidney dialysis patients in California have been stymied in Sacramento by the dialysis corporations, which spent
This initiative measure is submitted to the people in accordance with the provisions of Article II, Section 8, of the California Constitution. This initiative measure amends and adds sections to the Health
More informationDEPARTMENT OF HEALTH & Hl'NIAfV SERVICES Public Hcaffh Scn-ice WARNING LETTER
DEPARTMENT OF HEALTH & Hl'NIAfV SERVICES Public Hcaffh Scn-ice Food and Drug Administration 9200 CCorporate Bl%d. RockOlc MD 20550 WARNING LETTER VIA FEDERAL EXPRESS MP 4 2007 William D. Tobler, MD Mayfield
More informationDrug and Medical Device Registration FAQ
Drug and Medical Device Registration FAQ Contents Types of Submissions... 3 When is it appropriate to submit a new application form F-2?... 3 Do I need to submit a new application for a new or changed
More informationSummary of The San Mateo/Estero Municipal Improvement District Wastewater Treatment Plant
Issue Background Findings Conclusions Recommendations Responses Attachments Summary of The San Mateo/Estero Municipal Improvement District Wastewater Treatment Plant A Work in Progress Issue Has the City
More informationComplaint Handling and Medical Device Reporting (MDRs)
Complaint Handling and Medical Device Reporting (MDRs) FDA Small Business Regulatory Education for Industry (REdI) Bethesda, MD September 26, 2013 Andrew Xiao Consumer Safety Officer, Postmarket and Consumer
More informationColorado Oil and Gas Conservation Commission Enforcement Program
Colorado Oil and Gas Conservation Commission Enforcement Program Operator and Local Government Training Rifle * Durango * Longmont * Limon Dave Andrews and Bob Frick Agenda Introduction Executive Order
More informationAMENDED June 18, 2015 By Certified Mail and Facsimile
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services Midwest Division of Survey and Certification Chicago Regional Office 233 North Michigan Avenue, Suite 600 Chicago, IL 60601-5519
More informationSECTION 3 GUIDEBOOK: POLICIES AND PROCEDURES
SECTION 3 GUIDEBOOK: POLICIES AND PROCEDURES 1 TABLE OF CONTENTS WHAT IS SECTION 3?... 5 WHY IS SECTION 3 IMPORTANT TO THE CITY?... 5 THE CITY S POLICIES REGARDING SECTION 3... 5 Section 3 Plan... 6 What
More informationFDA s Office of Regulatory Affairs: Violation Trends & Medical Device Update
FDA s Office of Regulatory Affairs: Violation Trends & Medical Device Update Ginger M. Sykes Supervisory Consumer Safety Officer Salt Lake City Resident Post Office of Regulatory Affairs U.S. Food and
More informationCLINICAL LABORATORY IMPROVEMENT AMENDMENTS OF 1988: HOW TO ASSURE QUALITY LABORATORY SERVICES
CLINICAL LABORATORY IMPROVEMENT AMENDMENTS OF 1988: HOW TO ASSURE QUALITY LABORATORY SERVICES OVERVIEW In response to public health concerns over largely unregulated laboratory services, Congress enacted
More informationFLORIDA DID NOT ALWAYS VERIFY CORRECTION OF DEFICIENCIES IDENTIFIED DURING SURVEYS OF NURSING HOMES PARTICIPATING IN MEDICARE AND MEDICAID
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL FLORIDA DID NOT ALWAYS VERIFY CORRECTION OF DEFICIENCIES IDENTIFIED DURING SURVEYS OF NURSING HOMES PARTICIPATING IN MEDICARE AND MEDICAID
More informationCh. 55 NONCARRIER RATES AND PRACTICES CHAPTER 55. NONCARRIER RATES AND PRACTICES
Ch. 55 NONCARRIER RATES AND PRACTICES 52 55.1 CHAPTER 55. NONCARRIER RATES AND PRACTICES Subch. Sec. A. DISCONTINUATION OF SERVICE... 55.1 B. TERMINATION OF UTILITY SERVICE TO HEALTH CARE FACILITIES...
More informationFISCAL YEAR FAMILY SELF-SUFFICIENCY PROGRAM GRANT AGREEMENT (Attachment to Form HUD-1044) ARTICLE I: BASIC GRANT INFORMATION AND REQUIREMENTS
1 1 1 1 1 1 1 1 0 1 0 1 0 1 0 1 FISCAL YEAR 01 FAMILY SELF-SUFFICIENCY PROGRAM GRANT AGREEMENT (Attachment to Form HUD-) ARTICLE I: BASIC GRANT INFORMATION AND REQUIREMENTS 1. This Agreement is between
More informationFSMA User Guide. Food Safety Modernization Act Guide
Food Safety Modernization Act Guide The Food Safety Modernization Act of 2011 (FSMA), the first major overhaul of food safety legislation in more than 70 years, gives FDA the new job of building a modern,
More informationFSMA Implementation FDA s Preventive Controls Rules
FSMA Implementation FDA s Preventive Controls Rules 2016 National Association of Dairy Regulatory Officials Annual Meeting July 11, 2016 CAPT Robert (Bob) Hennes, MST Leader Presentation Overview FSMA
More informationSAFETY ACTION NOTICE By arrangement with the Scottish Executive Health Department
SAFETY ACTION NOTICE By arrangement with the Scottish Executive Health Department BAXTER IPUMP, APII AND PCAII INFUSION PUMPS: DELIVERY OF UNREQUESTED PCA DOSES AND/OR AIR TO THE PATIENT SUMMARY Page 1
More informationNotice of Initiation of Disqualification Proceeding And Opportunity to Explai n
NS-71- DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Center for Biologics Evaluation an d Research 1401 Rockville Pike Rockville MD 20852-1448 Notice of Initiation of Disqualification
More informationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO AUDIT SERVICES. UCSF Medical Center Hospital Charge Capture - Emergency Services Project #
, SAN FRANCISCO AUDIT SERVICES UCSF Medical Center Hospital Charge Capture - Emergency Services Project #13-024 June 2013 Performed by: Sugako Amasaki, Principal Auditor Julia Travous, Manager (Protiviti)
More informationGuidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA
Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
More informationStandards, Guidelines, and Regulations
Standards, Guidelines, and Regulations Theresa C. Stec BA, MT(ASCP) Biovigilance Program Manager Surgical System Administrator Perioperative Services Baystate Medical Center Springfield, MA Standards,
More informationOverview of the National Institute for Occupational Safety and Health Respirator Approval Program and Post Market Activities
Overview of the National Institute for Occupational Safety and Health Respirator Approval Program and Post Market Activities Jeffrey Peterson Deputy Chief, Conformity Verification and Standards Development
More informationREVISION: This revised Management Directive (MD) updates TSA MD , dated January 29, 2004.
OFFICE OF OCCUPATIONAL SAFETY, HEALTH, AND ENVIRONMENT TSA MANAGEMENT DIRECTIVE No. 2400.3 REVISION: This revised Management Directive (MD) updates TSA MD 2400.3, dated January 29, 2004. SUMMARY OF CHANGES:
More informationENFIELD BOARD OF EDUCATION ENFIELD, CONNECTICUT. USE OF AUTOMATIC EXTERNAL DEFIBRILLATORS (AED s) BY SCHOOL PERSONNEL
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 ENFIELD BOARD OF EDUCATION ENFIELD, CONNECTICUT USE OF AUTOMATIC EXTERNAL
More informationTHE AMERICAN OSTEOPATHIC BOARD OF EMERGENCY MEDICINE APPLICATION FOR CERTIFICATION AND EXAMINATION (TYPE WRITTEN OR LEGIBLY PRINTED)
THE AMERICAN OSTEOPATHIC BOARD OF EMERGENCY MEDICINE APPLICATION FOR CERTIFICATION AND EXAMINATION (TYPE WRITTEN OR LEGIBLY PRINTED) I hereby make application to the American Osteopathic Board of Emergency
More informationFebruary 19, Internal Audit Report Child Care Licensing Department of Health and Human Services
Internal Audit Report 2009 05 Department of Introduction. The Section (Section) is funded with a $1.4 million State grant administered by the Department of. Anchorage Municipal Code (AMC) Title 16.55,
More informationFinal Operator Certification Rule
Final Operator Certification Rule Deni Gray Operator Certification Program Manager Terri Notestine CCC Program Manager 2014 BAT Forum Mission To protect the health of the people of Washington State by
More information